Changes to health technology evaluation
We're changing how we assess new drugs, devices, diagnostics and digital technologies to provide faster and fairer access in the NHS.
Find out more
- The changes will improve the way we work with patients, the NHS and the life sciences industry.
- Find out what's changing and share your views.
Guidance
Evidence-based recommendations developed by independent committees, including professionals and lay members, and consulted on by stakeholders.
Get involved
We want you to be involved in our work. Tell us what matters to you, your organisation or your community.
There are many ways you can get involved as a healthcare professional or a member of the public.
About us
Find out more about
and how we support
The NICE strategy 2021 to 2026 sets out an ambitious vision for our future.
Latest news
-
All managers should be given the skills to support employees with mental health issues, NICE and PHE have said in new guidance.
-
Professor Leng has spent more than 20 years working at NICE
-
NICE has today (9 September 2021) published final draft guidance which recommends tofacitinib (also known as Xeljanz and made by Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.
-
NICE has today (8 September 2021) published final draft guidance which now recommends apalutamide (also called Erleada and made by Janssen) plus androgen deprivation therapy for treating prostate cancer in adults
Explore NICE
Into practice
Resources to help you use our guidance and quality standards
Financial planning
Advice and tools to help you make the best use of your resources
Antimicrobial resistance
View our antimicrobial prescribing guidelines
Our role in patient safety
Our guidelines make evidence-based, best practice recommendations.
Find journals and databases
Access to a range of journals and other evidence-based resources.